SOPHiA GENETICS CSO sells 4,000 shares at $7.88

Rhea-AI Filing Summary

SOPHiA GENETICS SA (SOPH) reports that Chief Scientific Officer Zhenyu Xu sold 4,000 Ordinary Shares on September 14, 2026 at a weighted average price of about $7.88 per share, in transactions executed under a duly adopted Rule 10b5-1(c) trading plan, leaving him with 552,887 shares held directly.

Insider Trade Summary 10b5-1

Net Seller: 4,000 shares

Net Sell 1 txn

Insider Xu Zhenyu

Role Chief Scientific Officer

Sold 4,000 shs ($32K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2	4,000	$7.8844	$32K

Holdings After Transaction: Ordinary Shares — 552,887 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.78 to $7.99, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 4,000 shares Weighted average sale price: $7.8844 per share Sale price range: $7.78–$7.99 per share +2 more

5 metrics

Shares sold 4,000 shares Ordinary Shares sold by Chief Scientific Officer on September 14, 2026

Weighted average sale price $7.8844 per share Average price for the 4,000 shares sold on September 14, 2026

Sale price range $7.78–$7.99 per share Range of individual transaction prices for the reported sale

Shares held after transaction 552,887 shares Direct holdings of Zhenyu Xu following the September 14, 2026 sale

Transactions reported as sales 1 sale transaction Non-derivative Ordinary Shares transaction reported in this Form 4

Key Terms

Rule 10b5-1(c), weighted average price, Ordinary Shares, trading plan

4 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Ordinary Shares financial

"The shares were sold in multiple transactions at prices ranging from $7.78 to $7.99, inclusive."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

trading plan financial

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

A trading plan is a written set of rules an investor follows about what to buy or sell, when to enter and exit positions, and how much risk to accept—like a travel itinerary that maps the route, stops, and budget before a trip. It matters because it helps remove emotional decisions during market swings, enforces discipline, and makes performance easier to review and improve, reducing the chance of costly impulsive moves.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SOPH disclose for Chief Scientific Officer Zhenyu Xu?

SOPHiA GENETICS SA disclosed that Chief Scientific Officer Zhenyu Xu sold 4,000 Ordinary Shares on September 14, 2026 in a reported open-market or private transaction, based on the Form 4 data.

At what price were the SOPH shares sold in this Form 4 filing?

The reported sale by Zhenyu Xu used a weighted average price of $7.8844 per share. A footnote states the shares were sold in multiple transactions at prices ranging from $7.78 to $7.99, inclusive.

How many SOPH shares did the insider retain after the reported sale?

After selling 4,000 Ordinary Shares, Chief Scientific Officer Zhenyu Xu held 552,887 shares directly. This figure is reported as his total direct holdings following the transaction on September 14, 2026.

Was the SOPH insider sale made under a Rule 10b5-1 trading plan?

Yes. A footnote states the transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c), indicating it was executed according to a pre-established plan rather than ad hoc timing.

What price range did the SOPH insider’s share sales cover?

The filing explains that the shares were sold in multiple transactions at prices ranging from $7.78 to $7.99, inclusive, with the reported $7.8844 figure representing a weighted average price across those trades.

Does the filing offer more detail on the individual SOPH trade prices?

Yes. A footnote states that Zhenyu Xu undertakes to provide, upon written request, full information on the number of shares sold at each separate price within the $7.78 to $7.99 range to the issuer, any security holder, or SEC staff.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:01 PM Accepted by SEC EDGAR 09/16/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Zhenyu

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/14/2026		S		4,000(1)	D	$7.8844(2)	552,887	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.78 to $7.99, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Zhenyu Xu	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)